VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Completed · Phase 2
Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
In brief
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die. Hydroxyurea may help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving VNP40101M with hydroxyurea works in treating patients with acute myelogenous leukemia or high-risk myelodysplasia.
Key facts
- Study ID
- NCT00083187
- Run by
- Vion Pharmaceuticals
- People needed
- 230
- Starts
- 2005-11-01
- Expected to finish
- 2008-08-01
- Last updated by the study team
- 2013-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- M.D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes — Marseille, France
- King's College Hospital — London, England, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.